To determine the impact of Herceptin and LCN2 targeting on the disruption of tumor emboli, we treated IC3 tumor emboli with Herceptin-conjugated liposomes loaded with siRNA-NC or siRNA-LCN2. The gene discussed is LCN2; the disease is neoplasm.